Barclays Initiates Coverage of Chemours at Equal-Weight
Fintel reports that on October 13, 2026, Barclays initiated coverage of Chemours (NYSE:CC) (BMV:CC) with a Equal-Weight recommendation.
Chemours, based in the United States, operates primarily in the chemicals industry. Founded as a spin-off from DuPont in 2015, the company specializes in the production of high-performance chemicals used in various sectors including refrigeration, electronics, and industrial processes. Its leading products include brands like Teflon and Ti-Pure. The company is also involved in sustainability projects, such as its Opteon range of refrigerants designed to reduce environmental impact with low global warming potential, aligning with its commitment to Responsible Care®.
On the day of the rating action, October 13, 2026, the stock closed at $13.20. This follows a close of $13.39 on the previous session, October 12, 2026. Over a one-week period, the stock experienced a price change of -6.29% from a baseline close of $14.08 on October 6, 2026. Over a one-month period, the price change was -12.21% from a baseline close of $15.03 on September 11, 2026.
As of October 2, 2026, the current consensus target mean for Chemours was $19.31, with a median target of $18.36. This mean target represents an implied change of +46.31%. Previously, on September 15, 2026, the prior consensus target mean was $19.89, representing a consensus target revision of -2.94%.
In terms of broader analyst recommendations, as of the September 1, 2026 period, the current recommendations totaled 18, resulting in 61.1% positive, 33.3% hold, and 5.6% negative recommendations. This represents a shift from the prior period of August 1, 2026, where the total of 18 recommendations translated to 66.7% positive, 27.8% hold, and 5.6% negative recommendations.
Prior to the initiation by Barclays, other financial institutions updated their outlooks on Chemours. On October 5, 2026, UBS maintained its Neutral rating, keeping the recommendation at Neutral. Before that, on September 30, 2026, Mizuho maintained its Outperform rating, keeping the recommendation at Outperform.
Chemours last reported earnings on August 4, 2026. The company reported an actual EPS of 0.42, compared to an estimate of 0.4317, representing an EPS surprise of -2.71%. Actual revenue for the quarter was $1,591,000,000.00, which was below the estimated revenue of $1,703,680,327.00. The company's upcoming earnings date is scheduled for October 28, 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 13, 2026 | Barclays | Equal-Weight | initiated coverage | |
| October 5, 2026 | UBS | Neutral | Neutral | maintained |
| September 30, 2026 | Mizuho | Outperform | Outperform | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.